Subtitle: Navigating Dravet Syndrome and Precision Neurology with High-Fidelity Ion Channel Reagents.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCN1A-targeted drug discovery. Select your modality for selective Nav1.1 modulation:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SCN1A Lentivirus Premade Particles. Full-length human Nav1.1 ORF with native topology. HEK293T packaged. Titer >1x10^8 TU/mL. Sequence Verified. | View SCN1A Products |
| Antigen | SCN1A Extracellular Loops. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View SCN1A Products |
| Mutant Panel | SCN1A Dravet Mutant Lentivirus Collection. Key clinical mutations (C truncation, R1648H, etc.) for mechanism studies. Endotoxin <1 EU/µg. | View SCN1A Products |
| Benchmark Ab | Anti-SCN1A Reference Antibody. Recombinant positive control for target binding assays. Clone SCN1A-ECD-02 for FACS/Western. | View SCN1A Products |
| Validator | SCN1A siRNA Set (3 unique sequences). For knockdown verification in native cell lines. >85% mRNA reduction at 48h. | View SCN1A Products |
| Related Target A | SCN2A (Nav1.2). Excitatory neuron counterpart; critical for selectivity screening vs. inhibitory Nav1.1. | View SCN2A Products |
| Related Target B | SCN1B (Nav beta1). Voltage-gated sodium channel beta subunit essential for proper channel kinetics. | View SCN1B Products |
| Related Target C | SCN8A (Nav1.6). Node of Ranvier/AIS dominant channel; off-target liability assessment. | View SCN8A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Expression (Ion Channel) | Lentivirus Premade Particles for stable, full-length mammalian expression (HEK293/CHO) preserving native conformation. |
| Subfamily counter screening (Nav1.2, Nav1.6) | Ortholog and homolog lentivirus vectors available strictly verified by sequence validation. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in endogenous systems. |
| Cross-species translation (Human/Mouse/Rat) | Ortholog Lentivirus available with species-matched signal peptides; Sequence identity verified by NGS. |
| Nav Channel Family Selectivity (SCN1A vs SCN2A/SCN3A/SCN4A/SCN5A/SCN8A/SCN9A) | Full-length ORF Lentivirus panel for counter-screening; Native conformation preserved in mammalian membrane. |
| ASO Mechanism Validation (Uptake/Nuclear Localization) | Native 5' UTR inclusion in ORF construct; Supports antisense target engagement studies. |
| Dravet Mutation Functional Profiling | Loss-of-function (LOF) and missense mutant library; Ready for patch-clamp validation. |
Live SCN1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (General)
- ➤ View Active Clinical Trials (Dravet Syndrome)
- ➤ Latest Resistance Research
- ➤ Latest ASO/Genetic Therapy Research
- ➤ Recent Patent Filings (General)
- ➤ Recent Patent Filings (Nav1.1 Modulators)
Global Clinical Landscape & Future Outlook
The race for SCN1A therapeutics is intensifying, with major players shifting focus from broad-spectrum antiepileptics to precision genetic medicines. SCN1A loss-of-function mutations cause Dravet syndrome by impairing inhibitory GABAergic interneurons, so therapies must selectively boost Nav1.1 activity without hyperactivating excitatory channels. Stoke Therapeutics' STK-001 (ASO) is advancing through Phase 2, and Encoded Therapeutics is pushing gene therapy candidates (AAV). The next wave of R&D is targeting mutation-agnostic approaches and Nav1.1/Nav1.6 balance modulators for broader epilepsy indications, including potential expansion into autism spectrum disorders. First-generation therapies are reaching the clinic, while precision delivery to the CNS and disease-modifying genetic interventions remain the key focus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO (Upregulation) | Stoke Therapeutics (STK-001), Ionis/Biogen | Dravet Syndrome (SCN1A haploinsufficiency) | ASO Uptake & Nuclear Localization Assay (Need full-length 5'UTR Lentivirus) |
| Gene Therapy (AAV) | Encoded Therapeutics, Taysha Gene Therapies | Dravet Syndrome, Generalized Epilepsy | Functional Expression Validation (Need high-titer Lentivirus for primary neuron transduction) |
| Small Molecule Potentiators | Praxis Precision Medicines (PRAX-562), Xenon Pharma | Dravet, Autism Spectrum Disorders | Selectivity Panel (Need SCN1A, SCN2A, SCN8A Lentivirus array for patch-clamp) |
| Targeted Protein Modulation | Preclinical Biotech | Gain-of-function Epilepsies | Mutant vs WT Discrimination (Need Dravet-specific mutant proteins) |
Key Functional Domains and Mutations
SCN1A contains an IQ domain (UniProt P35498) critical for calmodulin binding and channel regulation. Clinically relevant mutations include the DRVT variant (VAR_073441), GEFSP2 (VAR_064229, likely benign), and several epilepsy-associated variants of uncertain significance (VAR_073442). These variants highlight the necessity of functional validation using mutant lentivirus panels and underscore the genetic heterogeneity that must be addressed in drug discovery.
Conclusion
SCN1A drug discovery is transitioning from symptomatic treatment to disease-modifying therapies. TarMart's comprehensive Lentivirus toolkit supports all major modalities—ASO, gene therapy, small molecule—by enabling high-fidelity ion channel expression, selectivity screening, and mutation-specific functional profiling.